Logo

Ascletis Pharma Reports the Completion of Patient Enrollment of ASC22 (envafolimab) + Chidamide in Clinical Study for HIV Infection

Share this
Ascletis Pharma Reports the Completion of Patient Enrollment of ASC22 (envafolimab) + Chidamide in Clinical Study for HIV Infection

Ascletis Pharma Reports the Completion of Patient Enrollment of ASC22 (envafolimab) + Chidamide in Clinical Study for HIV Infection

Shots:

  • The company has completed the patient enrolment in the clinical study of ASC22 (1mg/kg, SC, q4w) + Chidamide (10mg, BIW) in 15 HIV-infected patients. The study focuses is to evaluating the efficacy of ASC22 + Chidamide on the viral reservoirs of latently infected cells
  • The results showed that HIV latency was reversed in the clinical study by blocking the PD-1/PD-L1 pathway & reinforced the case for combining PD-1/PD-L1 Ab with other therapies to lower the HIV reservoir of latently infected cells
  • ASC22 is designed to restore virus-specific immune responses for chronic viral inf. Chidamide is the selective HDACi targeting subtype 1, 2, 3 of class I & subtypes 10 of class IIb HDAC with a mechanism against epigenetic abnormality

Ref: PRNewswire| Image: Ascletis Pharma

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions